BluePrint Orphan
BluePrint Orphan is dedicated to accelerating investments in rare and orphan diseases with the mission of making patient lives better. They offer strategic advisory services, licensing strategy, opportunity assessment, and a range of healthcare and market access solutions. Their core capabilities include market access and forecasting, data management and analytics, global pricing and reimbursement, HEOR, marketing and messaging analytics, stakeholder advisory boards, and specialized reports on indications and therapeutics. They focus on creating robust analytic tools like RareValue to support investment decisions and portfolio planning in the rare disease market, and provide comprehensive forecasting and market access insights to guide clinical development and commercialization strategies.
Industries
Nr. of Employees
small (1-50)
BluePrint Orphan
Products
Decision-support model for rare and orphan disease investments
Interactive analytic tool to score and compare preclinical and clinical-stage opportunities across rare diseases using factors such as price, competition, severity, epidemiology and treatable population.
Patient forecast reports by indication
Reports providing global and country-specific patient estimates for specified indications using current epidemiology, natural-history data, and documented assumptions.
Revenue forecast reports by therapeutic
Reports projecting global and country-level revenues for therapeutics in development, combining patient forecasts, uptake assumptions, pricing and competitor impacts.
Searchable indication catalog
Alphabetical, searchable catalog of medical indications curated to support rapid reference and report generation for development and market assessments.
Searchable therapeutics catalog
Alphabetical, searchable catalog of therapeutics and compounds to support rapid reference for competitive and development assessments; supports on-demand addition of therapeutics with a stated one-business-day turnaround.
RareValue
An interactive decision support system and analytical model designed to assess investment potential, epidemiology, and commercial opportunities for preclinical and clinical stage rare and orphan disease treatments.
Decision-support model for rare and orphan disease investments
Interactive analytic tool to score and compare preclinical and clinical-stage opportunities across rare diseases using factors such as price, competition, severity, epidemiology and treatable population.
Patient forecast reports by indication
Reports providing global and country-specific patient estimates for specified indications using current epidemiology, natural-history data, and documented assumptions.
Revenue forecast reports by therapeutic
Reports projecting global and country-level revenues for therapeutics in development, combining patient forecasts, uptake assumptions, pricing and competitor impacts.
Searchable indication catalog
Alphabetical, searchable catalog of medical indications curated to support rapid reference and report generation for development and market assessments.
Searchable therapeutics catalog
Alphabetical, searchable catalog of therapeutics and compounds to support rapid reference for competitive and development assessments; supports on-demand addition of therapeutics with a stated one-business-day turnaround.
RareValue
An interactive decision support system and analytical model designed to assess investment potential, epidemiology, and commercial opportunities for preclinical and clinical stage rare and orphan disease treatments.
Services
Consulting to produce launch forecasts, payer scenarios, and market-access plans using epidemiology, expert input, and scenario analysis.
Project-based HEOR and real-world evidence projects including burden-of-disease, claims and literature analyses, and expert validation to quantify clinical and economic value.
Design, build and management of client databases and dashboards to integrate claims, rebate and clinical data and to support rapid visualization and synthesis.
Analytic modelling of pricing strategies, payer segmentation, contracting scenarios and value-based approaches to estimate impacts on net revenue.
Sourcing, evaluation and negotiation support for acquisitions, in-licensing, out-licensing and collaborations, including valuation and milestone structuring.
Design and facilitation of advisory boards and structured interviews with clinicians, payers, and patient advocates to inform development, trial design, and market access.
Consulting to produce launch forecasts, payer scenarios, and market-access plans using epidemiology, expert input, and scenario analysis.
Project-based HEOR and real-world evidence projects including burden-of-disease, claims and literature analyses, and expert validation to quantify clinical and economic value.
Design, build and management of client databases and dashboards to integrate claims, rebate and clinical data and to support rapid visualization and synthesis.
Analytic modelling of pricing strategies, payer segmentation, contracting scenarios and value-based approaches to estimate impacts on net revenue.
Sourcing, evaluation and negotiation support for acquisitions, in-licensing, out-licensing and collaborations, including valuation and milestone structuring.
Design and facilitation of advisory boards and structured interviews with clinicians, payers, and patient advocates to inform development, trial design, and market access.
Expertise Areas
- Market access and launch forecasting
- Health economics and outcomes research (HEOR) and real-world evidence
- Pricing and reimbursement modelling and policy analysis
- Rare disease epidemiology and patient-population forecasting
Key Technologies
- Interactive decision-support modelling and scenario/sensitivity analysis
- Dashboard and data-visualization platforms
- Claims data analytics and longitudinal cohort analysis
- EMR/clinical data mining
News & Updates
Check out the latest blog post to learn about the pandemic's impact on the orphan space.
BluePrint Orphan now offers Out-License services and On-Site Workshops to facilitate licensing and development collaborations.
Insights on current trends in biopharma, including COVID-19 impacts, licensing, and therapeutic development.
Check out the latest blog post to learn about the pandemic's impact on the orphan space.
BluePrint Orphan now offers Out-License services and On-Site Workshops to facilitate licensing and development collaborations.
Insights on current trends in biopharma, including COVID-19 impacts, licensing, and therapeutic development.